# Southern Peptide Co — Recovery & Tissue Repair Research Peptides > Southern Peptide Co briefs the published research on three Recovery & Tissue Repair peptides — GHK-Cu, TB-500, and the Wolverine blend — through a wound-healing and skin-barrier repair lens. A digest, not a vendor or clinic. A citation-anchored read on GHK-Cu, TB-500, and the Wolverine blend — what the wound-healing and skin-barrier repair literature shows, what research-use communities report, and where the evidence stops. ## The short version Southern Peptide Co is a briefing, not a store. It tracks what the published research literature says about three peptides grouped under **recovery and tissue repair**: GHK-Cu, TB-500, and a research-community pairing of the two called Wolverine (which specifically combines TB-500 with a separate peptide, BPC-157). Each is studied for a different piece of how injured tissue rebuilds itself — the skin barrier, the collagen matrix, cell migration, new blood-vessel growth. GHK-Cu is a small copper-binding peptide that occurs naturally in human plasma and is well established as a topical cosmetic ingredient for skin and hair. TB-500 is a synthetic fragment of a larger repair protein, studied mostly in animals for its effect on cell movement and scar formation. Wolverine sits at the far edge of the evidence: two peptides used together with no controlled study of the pairing itself. This briefing reports what was studied, in what model, and what was found. It recommends no dose and no course of action, and nothing here is for sale. ## The wound-healing and skin-barrier repair frame The organizing question on this briefing is not which peptide is strongest — it is how each one is reasoned to contribute to **wound healing and skin-barrier repair**, the lens under which these three are grouped. [GHK-Cu](/ghk-cu) works at the matrix level: it is a documented driver of collagen, elastin, and glycosaminoglycan synthesis in skin, with the deepest human evidence of the three compounds — entirely in topical, dermatological contexts [4][6]. [TB-500](/tb-500) works at the cellular level: as a synthetic fragment of thymosin beta-4, it is reasoned to influence the actin dynamics that govern cell migration, re-epithelialization, and new blood-vessel growth in tissue-injury models [10]. [Wolverine](/wolverine) is the research community's attempt to stack two separate repair mechanisms in one protocol — TB-500's actin-based migration signal paired with BPC-157's angiogenic, VEGFR2-driven cytoprotective signal — reasoned as complementary, though no controlled study has tested the combination itself [8][13]. Reading the three together maps the injury-repair problem from three angles: rebuild the matrix (GHK-Cu), move the cells (TB-500), and — per the untested blend hypothesis — attempt both at once (Wolverine). ## What are research peptides Peptides are short chains of amino acids — the building blocks of proteins, scaled down. The three compounds on this briefing are structurally and regulatorily distinct from one another, and that distinction matters more here than it does for most peptide categories. GHK-Cu (glycyl-histidyl-lysine bound to copper) occurs naturally in human blood plasma and declines with age. Topically, as Copper Tripeptide-1, it is a legal, widely marketed cosmetic ingredient with a multi-decade safety record. TB-500 is different in kind: a synthetic, N-acetylated fragment (Ac-LKKTETQ) of a larger natural protein, thymosin beta-4, with no approved use, cosmetic or otherwise — and neither does the blend that pairs it with BPC-157. Community suppliers describe these as laboratory research chemicals; none is an approved drug for systemic or injectable use, and this briefing does not suggest otherwise. Every dosing figure that appears on this site is exactly the figure used in a cited study — never a suggestion for a person to follow. ## A note on how this briefing reads the evidence This briefing keeps a clinician's habit of separating what is documented from what is reported, and what is reported from what is unknown. Each compound page states what has been studied, in which model — human, animal, or cell culture — and what has not. GHK-Cu carries the most human data, drawn from small dermatology and hair trials. TB-500's efficacy evidence is almost entirely preclinical; its one completed human trial tested a different, full-length molecule, not the fragment sold as TB-500. Wolverine's evidence base is the sum of its two components' separate literatures — there is no published study of the blend itself. Community-reported effects appear on every page, labeled clearly as self-reported and not clinical findings, and never attached to a dose. See the [references list](/references) for every source cited across the site. --- An independent tissue-repair research briefing: what is documented, what is reported, and what remains unknown — never a prescription.